Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25654272 | 1.00 | HRH3 (0.40) | HRH3LIPCLIPGDRD2GNAI3 | |
| SCHEMBL25972078 | 0.89 | NPC1 (0.46) | HRH3DRD2GNAI3GNAO1GNAI1 | |
| SCHEMBL9277201 | 0.88 | GNAO1 (0.46) | DRD2GNAI3GNAO1GNAI1DRD3 | |
| SCHEMBL26280657 | 0.87 | LIPC (0.38) | HRH3LIPCLIPGGNAI3GNAO1 | |
| SCHEMBL17033973 | 0.87 | LIPC (0.38) | HRH3LIPCLIPGGNAI3GNAO1 | |
| SCHEMBL26280663 | 0.87 | LIPC (0.38) | HRH3LIPCLIPGGNAI3GNAO1 | |
| SCHEMBL26227368 | 0.87 | GBA1 (0.34) | HRH3DRD2NPC1DRD3DRD1 | |
| SCHEMBL23806130 | 0.84 | HRH3 (0.33) | HRH3DRD2NPC1DRD3DRD1 | |
| SCHEMBL14886377 | 0.81 | LIPC (0.39) | LIPCLIPGGNAI3GNAO1GNAI1 | |
| SCHEMBL12204126 | 0.81 | LIPC (0.39) | LIPCLIPGGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885LIPC 2188/4885LIPG 2521/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885LIPC 2188/4885LIPG 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.